Desiree Bos
Overview
Explore the profile of Desiree Bos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
96
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buitinga M, Cohrs C, Eter W, Claessens-Joosten L, Frielink C, Bos D, et al.
Diabetes
. 2020 Aug;
69(11):2246-2252.
PMID: 32843570
Glucagon-like peptide 1 receptor (GLP-1R) imaging with radiolabeled exendin has proven to be a powerful tool to quantify β-cell mass (BCM) in vivo. As GLP-1R expression is thought to be...
2.
Boss M, Bos D, Frielink C, Sandker G, Bronkhorst P, van Lith S, et al.
J Nucl Med
. 2020 May;
61(11):1588-1593.
PMID: 32385165
Treatment of hyperinsulinemic hypoglycemia is challenging. Surgical treatment of insulinomas and focal lesions in congenital hyperinsulinism is invasive and carries major risks of morbidity. Medication to treat nesidioblastosis and diffuse...
3.
Boss M, Bos D, Frielink C, Sandker G, Ekim S, Marciniak C, et al.
J Nucl Med
. 2020 Jan;
61(7):1066-1071.
PMID: 31924726
The treatment of choice for insulinomas and focal lesions in congenital hyperinsulinism (CHI) is surgery. However, intraoperative detection can be challenging. This challenge could be overcome with intraoperative fluorescence imaging,...
4.
Joosten L, Brom M, Peeters H, Bos D, Himpe E, Bouwens L, et al.
Mol Pharm
. 2019 Jul;
16(9):4024-4030.
PMID: 31345042
Objective: Targeting the glucagon-like peptide-1 receptor with radiolabeled exendin is a very promising method to noninvasively determine the β cell mass in the pancreas, which is needed to unravel the...
5.
Brom M, Joosten L, Frielink C, Peeters H, Bos D, van Zanten M, et al.
Diabetes
. 2018 Jul;
67(10):2012-2018.
PMID: 30045920
The changes in β-cell mass (BCM) during the development and progression of diabetes could potentially be measured by radionuclide imaging using radiolabeled exendin. In this study, we investigated the potential...
6.
Odenthal J, Rijpkema M, Bos D, Wagena E, Croes H, Grenman R, et al.
Sci Rep
. 2018 Jul;
8(1):10467.
PMID: 29992954
Head and neck squamous cell carcinoma (HNSCC) is an often highly invasive tumor, infiltrating functionally important tissue areas. Achieving complete tumor resection and preserving functionally relevant tissue structures depends on...
7.
Eter W, van der Kroon I, Andralojc K, Buitinga M, Willekens S, Frielink C, et al.
Sci Rep
. 2017 Aug;
7(1):7232.
PMID: 28775287
Pancreatic islet transplantation is a promising therapy for patients with type 1 diabetes. However, the duration of long-term graft survival is limited due to inflammatory as well as non-inflammatory processes...
8.
Willekens S, van der Kroon I, Bos D, Joosten L, Frielink C, Boerman O, et al.
Diabetes Obes Metab
. 2016 Dec;
19(4):604-608.
PMID: 27987245
A non-invasive imaging method to monitor islet grafts could provide novel and improved insight into the fate of transplanted islets and, potentially, monitor the effect of therapeutic interventions. Therefore, such...
9.
van der Kroon I, Andralojc K, Willekens S, Bos D, Joosten L, Boerman O, et al.
J Nucl Med
. 2016 Jan;
57(5):799-804.
PMID: 26795287
Unlabelled: Islet transplantation is a promising treatment for type 1 diabetic patients. However, there is acute as well as chronic loss of islets after transplantation. A noninvasive imaging method that...
10.
Eter W, Bos D, Frielink C, Boerman O, Brom M, Gotthardt M
Sci Rep
. 2015 Oct;
5:15521.
PMID: 26490110
Islet transplantation is a novel promising strategy to cure type 1 diabetes. However, the long-term outcome is still poor, because both function and survival of the transplant decline over-time. Non-invasive...